Trevi Therapeutics (TRVI)
(Delayed Data from NSDQ)
$2.78 USD
+0.24 (9.45%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $2.78 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
D Value F Growth C Momentum F VGM
Income Statements
Fiscal Year end for Trevi Therapeutics, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 0 | 0 | 0 | 0 | 0 |
Cost Of Goods | 0 | 0 | 0 | 0 | 0 |
Gross Profit | 0 | 0 | 0 | 0 | 0 |
Selling & Adminstrative & Depr. & Amort Expenses | 34 | 30 | 32 | 32 | 27 |
Income After Depreciation & Amortization | -34 | -30 | -32 | -32 | -27 |
Non-Operating Income | 5 | 2 | 0 | 0 | 1 |
Interest Expense | 0 | 1 | 1 | 0 | 0 |
Pretax Income | -29 | -29 | -34 | -33 | -26 |
Income Taxes | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -29 | -29 | -34 | -33 | -26 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -29 | -29 | -34 | -33 | -26 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -34 | -29 | -32 | -32 | -27 |
Depreciation & Amortization (Cash Flow) | 0 | 1 | 1 | 0 | 0 |
Income After Depreciation & Amortization | -34 | -30 | -32 | -32 | -27 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 99.03 | 64.54 | 22.84 | 18.06 | 11.74 |
Diluted EPS Before Non-Recurring Items | -0.29 | -0.45 | -1.49 | -1.81 | -2.28 |
Diluted Net EPS (GAAP) | -0.29 | -0.45 | -1.49 | -1.81 | -2.28 |
Fiscal Year end for Trevi Therapeutics, Inc falls in the month of December .
All items in Millions except EPS data.
3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 | |
---|---|---|---|---|---|
Sales | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Cost Of Goods | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | NA | 0.00 | 0.00 | 0.00 | 0.00 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 8.94 | 9.04 | 8.38 | 7.56 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | -8.94 | -9.04 | -8.38 | -7.56 |
Non-Operating Income | NA | 1.13 | 1.34 | 1.36 | 1.39 |
Interest Expense | NA | 0.00 | 0.00 | 0.15 | 0.23 |
Pretax Income | NA | -7.80 | -7.71 | -7.18 | -6.41 |
Income Taxes | NA | 0.00 | -0.01 | -0.03 | 0.01 |
Minority Interest | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | NA | -7.81 | -7.70 | -7.15 | -6.42 |
Extras & Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | NA | -7.82 | -7.70 | -7.15 | -6.40 |
Earnings Per Share Data | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 |
---|---|---|---|---|---|
Average Shares | NA | 99.49 | 99.33 | 98.70 | 98.61 |
Diluted EPS Before Non-Recurring Items | NA | -0.08 | -0.08 | -0.07 | -0.06 |
Diluted Net EPS (GAAP) | NA | -0.08 | -0.08 | -0.07 | -0.06 |